Hansa Biopharma AB Share Price Börse Stuttgart

Equities

24H

SE0002148817

Biotechnology & Medical Research

Delayed Börse Stuttgart 02:17:53 28/05/2024 pm IST 5-day change 1st Jan Change
3.582 EUR +3.29% Intraday chart for Hansa Biopharma AB +5.41% +47.95%

Financials

Sales 2024 * 239M 22.65M 20.85M 1.88B Sales 2025 * 343M 32.44M 29.86M 2.7B Capitalization 2.66B 252M 232M 20.93B
Net income 2024 * -735M -69.59M -64.05M -5.79B Net income 2025 * -712M -67.41M -62.05M -5.6B EV / Sales 2024 * 13.1 x
Net Debt 2024 * 474M 44.88M 41.31M 3.73B Net Debt 2025 * 733M 69.44M 63.91M 5.77B EV / Sales 2025 * 9.9 x
P/E ratio 2024 *
-3.46 x
P/E ratio 2025 *
-4.11 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 week+5.41%
Current month+44.50%
1 month+52.64%
3 months+21.51%
6 months+55.80%
Current year+47.95%
More quotes
1 week
3.23
Extreme 3.23
3.67
1 month
2.25
Extreme 2.248
3.67
3 years
1.72
Extreme 1.723
15.80
5 years
1.72
Extreme 1.723
27.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20/18/20
Chief Tech/Sci/R&D Officer 53 01/12
Chief Tech/Sci/R&D Officer 66 29/20/29
Members of the board TitleAgeSince
Director/Board Member 73 29/18/29
Chairman 61 30/22/30
Director/Board Member 59 22/19/22
More insiders
Date Price Change
28/24/28 3.582 +3.29%
27/24/27 3.468 -3.24%
24/24/24 3.584 -2.45%
23/24/23 3.674 +8.96%
22/24/22 3.372 +3.50%

Delayed Quote Börse Stuttgart, May 28, 2024 at 02:17 pm IST

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
39.92 SEK
Average target price
105 SEK
Spread / Average Target
+163.03%
Consensus